Oncology

Data shows 5-year benefit of venetoclax-rituximab for relapsed/refractory CLL

New data from the phase 3 MURANO trials demonstrated sustained progression-free survival with venetoclax-rituximab based combinations in patients with relapsed or refractorychronic lymphocytic leukaemia (CLL), according to a presentation at the virtual American Society of Hematology (ASH) Annual Meeting and Exposition. Data from the 5-year pivotal trial showed that venetoclax-rituximab...